Imipenem / Cilastatin / Relebactam (2) (Recarbrio®) – Bacterial infections, multiple indications
|Pharm. company||MSD Sharp & Dohme GmbH|
|G-BA procedure ID||2022-05-01-D-814|
|Therapeutic area||Infectious diseases|
|Reason for procedure||Initial assessment – Reserve antibiotic|
|Regulatory status||Reserve antibiotic|
|G-BA resolution "Anwendungsgebiet des Beschlusses" (German)|
Recarbrio is indicated for:
Treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults.
Treatment of bacteremia for which there is or is suspected to be an association with HAP or VAP in adults.
Treatment of infections with aerobic Gram-negative pathogens in adults with limited treatment options.
|a)||Adults with hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)|
|b)||Adults with bacteraemia for which there is an association with HAP or VAP or suspected|
|c)||Adults with infections due to aerobic gram-negative pathogens with limited treatment options|
9. Associated procedures
|Resolution||INN||Brand name||Indication||Patients||Additional benefit|
|23.11.2020 – 20.01.2022||Imipenem / Cilastatin / Relebactam||Recarbrio®||Pneumonia, Bacteriemia||n.d.|
|01.05.2022 – 03.11.2022||Imipenem / Cilastatin / Relebactam (2)||Recarbrio®||Bacterial infections, multiple indications||2,598 – 6,600|
<< List of all resolutions
The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.